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The lack of participation of India and 
China, who between them share 50% 
of the world’s burden of multidrug-
resistant (MDR) tuberculosis, is a 
major limitation of the Preserving 
Eﬀ ective TB Treatment (PETTS) study.1 
Despite this limitation, the ﬁ ndings of 
the PETTS investigators ﬁ nd great and 
ominous resonance in India.
Second-line drugs are prescribed 
with brazen impunity by a range of 
private practitioners in India, many of 
them not even allopaths. A study from 
Dharavi,2 Asia’s largest slum, located 
in the heart of Mumbai, showed that, 
of the 106 practitioners prescribing 
second-line drugs to a hypothetical 
patient with MDR tuberculosis, 60% 
were trained in one of the alternative 
systems of medicine (homoeopathy, 
ayurveda, or unani) that ﬂ ourish in 
India. Only ﬁ ve of these 106 physicians 
could write an appropriate prescription 
with a minimum of three new second-
line drugs in the right doses for a 
minimum recommended duration of 
18 months. Most respondents added a 
single second-line drug, which 70% of 
the time was a ﬂ uoroquinolone. More 
tragically, these inappropriate pre-
scriptions would be dispensed without 
any checks or safeguards in place, since 
tuberculosis prescriptions are not 
controlled in India and even the most 
inexperienced doctor can prescribe 
second-line drugs with impunity. India 
has 1 million chemists policed by just 
4000 drug inspectors, and even if laws 
Resistance to second-
line drugs in multidrug-
resistant tuberculosis
The cohort study by Tracy Dalton and 
colleagues (Oct 20, p 1406),1 which 
ﬁ nds that the prevalence of extensively 
drug-resistant (XDR) and second-line 
drug-resistant tuber culosis in nine 
countries is higher than current WHO 
estimates, conﬁ rms the alarming rates 
of resistance found by Medécins Sans 
Frontières (MSF). In our Uzbekistan 
tuberculosis programme,2 190 (27%) 
of 709 patients with MDR tuberculosis 
had pre-XDR disease (deﬁ ned as 
resistance to any ﬂ uoroquinolone or 
injectable second-line drug).
Dalton and colleagues1 found that 
previous treatment for MDR tuber-
culosis was the strongest risk factor 
for resistance. However, since they do 
not explain the indications for doing 
culture and drug-susceptibility testing 
in the study countries, these patients 
could be a select group with more 
previous exposure. Our Uzbekistan 
programme data are based on 
expanded access to culture and drug 
susceptibility testing to all patients 
suspected of having tuberculosis. 
With this approach we identiﬁ ed a 
higher than expected rate of MDR 
tuber culosis in new patients: 201 
(38%) of the 529 patients started on 
MDR tuberculosis treat ment in the 
ﬁ rst three quarters of 2012 had never 
been treated for tuberculosis before 
(Jane Greig, personal communication). 
This ﬁ nding highlights the extent to 
which MDR tuberculosis has become 
an epidemic in its own right.
It is important to ensure that 
new drug regimens are eﬀ ective 
against Mycobacterium tuberculosis 
with extensive resistance to both 
ﬁ rst-line and second-line drugs. To 
ignore second-line resistance would 
be to repeat the error made when 
ﬁ rst-line resistance was ignored in 
the early implementation of DOTS 
programmes.
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we did measure fractional exhaled 
nitric oxide for airway inﬂ am-
mation—a measurement that oﬀ ers 
high sensitivity and speciﬁ city—and 
found that there was no diﬀ erence 
between study groups at baseline 
or study entry. Nor did we screen for 
mycoplasma infection—a disorder that 
remains unclear in chronic cough, since 
treatment with low-dose erythromycin 
was found to have no eﬀ ect on cough 
frequency or severity.10 A clinical history 
of refractory cough after an infection is 
quite common and gabapentin could 
have a treatment role since central 
sensitisation is a possible mechanism.
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